

Amendments to the Claims:

A listing of all pending claims is presented below. Please amend the claims as indicated below:

1. (currently amended) A method for treating the clinical manifestations of a disorder characterized by dysregulation of the Growth Hormone/Insulin-like Growth Factor (GH/IGF) axis in a mammal comprising administering to the mammal an effective amount of an Insulin-like Growth Factor-I (IGF-I) variant wherein the amino acid residue at position 16, 25, or 49 or the amino acid residues at positions 3 and 49 of native-sequence human IGF-I are replaced with an alanine, a glycine, or a serine residue.
2. (currently amended) The method of claim 1 wherein the disorder is a hyperglycemic disorder, a renal disorder, congestive heart failure, hepatic failure, poor nutrition, a wasting syndrome, or a catabolic state wherein the Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) levels are increased relative to such levels in a mammal without such a disorder.
3. (original) The method of claim 1 wherein the disorder is a renal disorder.
4. (currently amended) The method of claim 3 wherein the renal disorder is chronic or acute renal failure.
5. (currently amended) The method of claim 3 further comprising administering to the mammal an effective amount of a renally-active peptide, sulfonyl-containing, sulfonamide-containing, angiotensin-converting enzyme inhibitor, or antibody molecule that promotes reabsorption or retention of electrolytes.
6. (original) The method of claim 1 wherein the mammal is human.
7. (currently amended) The method of claim 1 wherein both the amino acids acid residues at positions 3 and 49 of native sequence human IGF-I are replaced with alanine residues.

8. (withdrawn) A kit comprising a container containing a pharmaceutical composition containing an IGF-I variant wherein the amino acid residue at position 16, 25, or 49 or the amino acid residues at positions 3 and 49 of native-sequence IGF-I are replaced with an alanine, a glycine, or a serine residue, and instructions directing the user to utilize the composition for treating a disorder characterized by dysregulation of the GH/IGF axis in a mammal.

9. (withdrawn) The kit of claim 8 wherein the disorder is a hyperglycemic disorder, a renal disorder, congestive heart failure, hepatic failure, poor nutrition, a wasting syndrome, or a catabolic state wherein the IGFBP-1 levels are increased relative to such levels in a mammal without such a disorder.

10. (withdrawn) The kit of claim 8 wherein the disorder is a renal disorder.

11. (withdrawn) The kit of claim 10 further comprising a container containing a renally-active molecule.

12. (withdrawn) The kit of claim 10 wherein the disorder is chronic or acute renal failure.

13. (withdrawn) The kit of claim 8 wherein the mammal is human.

14. (withdrawn) The kit of claim 8 wherein both amino acids are replaced with alanine residues.